Capricor Therapeutics (CAPR) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Capricor Therapeutics (CAPR) over the last 9 years, with Q3 2025 value amounting to -$0.54.
- Capricor Therapeutics' EPS (Weighted Average and Diluted) fell 4210.53% to -$0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6, marking a year-over-year decrease of 5686.27%. This contributed to the annual value of -$1.15 for FY2024, which is 3807.68% down from last year.
- Per Capricor Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.54 for Q3 2025, which was down 4210.53% from -$0.57 recorded in Q2 2025.
- Capricor Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $0.02 for Q4 2023, and its period low was -$0.57 during Q2 2025.
- In the last 5 years, Capricor Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.28 in 2023 and averaged -$0.29.
- As far as peak fluctuations go, Capricor Therapeutics' EPS (Weighted Average and Diluted) surged by 10645.16% in 2023, and later tumbled by 109539.21% in 2024.
- Quarter analysis of 5 years shows Capricor Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then dropped by 19.23% to -$0.31 in 2022, then skyrocketed by 106.45% to $0.02 in 2023, then crashed by 1095.39% to -$0.2 in 2024, then plummeted by 171.25% to -$0.54 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.54 for Q3 2025, versus -$0.57 for Q2 2025 and -$0.2 for Q4 2024.